Taysha Gene Therapies (Taysha Gene Therapies) Cash-to-Debt : 2.04 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Taysha Gene Therapies's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.04.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Taysha Gene Therapies could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Taysha Gene Therapies's Cash-to-Debt or its related term are showing as below:

TSHA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.54 Med: 2.36 Max: No Debt
Current: 2.04

During the past 5 years, Taysha Gene Therapies's highest Cash to Debt Ratio was No Debt. The lowest was 0.54. And the median was 2.36.

TSHA's Cash-to-Debt is ranked worse than
67.3% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs TSHA: 2.04

Taysha Gene Therapies Cash-to-Debt Historical Data

The historical data trend for Taysha Gene Therapies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Taysha Gene Therapies Cash-to-Debt Chart

Taysha Gene Therapies Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

No Debt

2.36

1.47

2.36

Taysha Gene Therapies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													1.06	0.76	2.78	2.36	2.04

Competitive Comparison of Taysha Gene Therapies's Cash-to-Debt

For the Biotechnology subindustry, Taysha Gene Therapies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taysha Gene Therapies's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's Cash-to-Debt falls into.

Taysha Gene Therapies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Taysha Gene Therapies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	143.94	/	(1.646	+	59.461)
	=	2.36

Taysha Gene Therapies's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	123.98	/	(1.696	+	59.011)
	=	2.04

Taysha Gene Therapies (NAS:TSHA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Taysha Gene Therapies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247

Website

https://www.tayshagtx.com

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Executives

Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long	director	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam	officer: Chief Financial Officer	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii	10 percent owner	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc.	10 percent owner	2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc.	10 percent owner	600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad	officer: CMO and Head of R&D	C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino	director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape	director	C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235